Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Transcode Therapeutics Inc (RNAZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: RNAZ (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -90.11% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.61M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 1.33 | 52 Weeks Range 6.15 - 905.52 | Updated Date 07/10/2025 |
52 Weeks Range 6.15 - 905.52 | Updated Date 07/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -792.4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -94.84% | Return on Equity (TTM) -342.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1834000 | Price to Sales(TTM) - |
Enterprise Value 1834000 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.59 | Shares Outstanding 833619 | Shares Floating 780142 |
Shares Outstanding 833619 | Shares Floating 780142 | ||
Percent Insiders 0.15 | Percent Institutions 9.16 |
Upturn AI SWOT
Transcode Therapeutics Inc
Company Overview
History and Background
Transcode Therapeutics Inc. is a biopharmaceutical company focused on developing RNA therapeutics to treat cancers. Founded in 2010, they are pioneering a new class of targeted therapies designed to enhance the effectiveness of cancer treatments. Key milestones include developing TTX-MC138, their lead drug candidate, and advancing it through preclinical and clinical trials.
Core Business Areas
- RNA Therapeutics Development: Focuses on discovering and developing RNA-based therapeutics for the treatment of various types of cancer. This includes drug design, preclinical research, and clinical development.
- TTX Delivery Platform: Developing and optimizing a proprietary delivery platform for RNA therapeutics to improve their efficacy and reduce off-target effects. This is a core technology for enabling their drug candidates.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their lead drug candidates in cancer patients.
Leadership and Structure
Transcode Therapeutics Inc. is led by a management team with expertise in drug development, oncology, and business strategy. The organizational structure includes departments for research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- TTX-MC138: TTX-MC138 is Transcode Therapeutics' lead drug candidate, an siRNA therapeutic designed to target microRNA-10b (miR-10b) which is overexpressed in metastatic tumors. Currently in Phase 0 and Phase 1 clinical trials. Competitors include companies developing siRNA therapies and traditional cancer treatments, such as chemotherapy.
Market Dynamics
Industry Overview
The RNA therapeutics market is rapidly growing, driven by advancements in drug delivery technologies and increasing understanding of RNA's role in disease. The market is characterized by intense competition, with numerous companies developing novel RNA-based therapies for various diseases.
Positioning
Transcode Therapeutics Inc. is positioned as a pioneer in RNA therapeutics for cancer, with a focus on developing targeted therapies with improved efficacy and reduced toxicity. They are competing with larger pharmaceutical companies and other biotech firms in the RNA therapeutics space.
Total Addressable Market (TAM)
The TAM for RNA therapeutics in oncology is estimated to reach billions of dollars in the coming years. Transcode Therapeutics Inc. is positioned to capture a share of this market through the successful development and commercialization of their drug candidates.
Upturn SWOT Analysis
Strengths
- Proprietary TTX delivery platform
- Targeted RNA therapeutics approach
- Experienced management team
- Focus on unmet medical needs in oncology
Weaknesses
- Limited financial resources
- Dependence on a single lead drug candidate
- Early-stage development pipeline
- High risk of clinical trial failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of the pipeline with new drug candidates
- Positive clinical trial results
- Increasing investor interest in RNA therapeutics
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Economic downturn
Competitors and Market Share
Key Competitors
- MRNA
- ALNY
- IONS
Competitive Landscape
Transcode Therapeutics Inc. faces intense competition from established pharmaceutical companies and other biotech firms in the RNA therapeutics space. Its competitive advantage lies in its proprietary TTX delivery platform and its focus on developing targeted therapies for cancer.
Growth Trajectory and Initiatives
Historical Growth: Transcode Therapeutics Inc's growth has been primarily driven by its R&D activities and clinical trial progress. The company's revenue has been limited, but it has made significant progress in advancing its lead drug candidate.
Future Projections: Future growth is dependent on the successful completion of clinical trials and the potential commercialization of TTX-MC138 and other drug candidates. Analyst estimates vary widely, reflecting the inherent uncertainty in biotechnology investments.
Recent Initiatives: Recent strategic initiatives include advancing TTX-MC138 into later-stage clinical trials, exploring partnerships with larger pharmaceutical companies, and expanding its pipeline with new drug candidates.
Summary
Transcode Therapeutics Inc. is a development-stage biopharmaceutical company with a promising RNA therapeutic platform. The company's success hinges on the successful completion of clinical trials for its lead drug candidate and its ability to secure partnerships or funding. Its limited financial resources and dependence on a single drug candidate pose significant risks, while opportunities exist in expanding its pipeline and partnering with larger pharmaceutical companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share is estimated due to limited public data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Transcode Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-07-08 | Interim CEO, CFO, President, VP of Administration & Director Mr. Thomas A. Fitzgerald M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | |
Full time employees 7 | |||
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.